Artelo Biosciences, Inc. SEC filings ARTL

Artelo Biosciences, Inc. has 465 filings in SEC EDGAR's recent list, going back to Oct 8, 2014. Its latest annual report, Form ARS, was filed on Jun 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (other events). The company's fiscal year ends on December 31.

Artelo Biosciences, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Jun 5, 2026 Dec 31, 2025
10-K Annual report Feb 24, 2026 Dec 31, 2025
ARS Annual report to shareholders Dec 11, 2025 Dec 31, 2024
10-K Annual report Mar 3, 2025 Dec 31, 2024
ARS Annual report to shareholders Nov 8, 2024 Dec 31, 2023
10-K Annual report Mar 25, 2024 Dec 31, 2023
ARS Annual report to shareholders May 16, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2023 Dec 31, 2022
10-KT Transition report Mar 21, 2022 Dec 31, 2021
10-K Annual report Nov 29, 2021 Aug 31, 2021
10-K Annual report Nov 4, 2020 Aug 31, 2020
10-K/A Amended annual report Dec 18, 2019 Aug 31, 2019
10-K Annual report Nov 25, 2019 Aug 31, 2019
10-K Annual report Nov 29, 2018 Aug 31, 2018
10-K Annual report Nov 29, 2017 Aug 31, 2017
10-K/A Amended annual report Dec 1, 2016 Aug 31, 2016
10-K Annual report Nov 29, 2016 Aug 31, 2016
10-K Annual report Dec 11, 2015 Aug 31, 2015

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ARTL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Solana Beach, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1621221
Former names
REACTIVE MEDICAL INC. (until Apr 17, 2017); KNIGHT KNOX DEVELOPMENT CORP. (until Feb 6, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.